Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 3/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17823173 | 1.00 | PTGS1 (0.40) | PTGS1PTGS2KMT2ASMN1; SMN2HPGD | |
| SCHEMBL20864022 | 0.92 | KMT2A (0.38) | PTGS1PTGS2KMT2ASMN1; SMN2HPGD | |
| SCHEMBL21073942 | 0.92 | KMT2A (0.38) | PTGS1PTGS2KMT2ASMN1; SMN2HPGD | |
| SCHEMBL21073943 | 0.92 | KMT2A (0.38) | PTGS1PTGS2KMT2ASMN1; SMN2HPGD | |
| SCHEMBL17823177 | 0.91 | KDM4E (0.36) | KMT2ASMN1; SMN2HPGDALDH1A1MAPT | |
| SCHEMBL17823176 | 0.91 | KDM4E (0.36) | KMT2ASMN1; SMN2HPGDALDH1A1MAPT | |
| SCHEMBL22147094 | 0.91 | KMT2A (0.41) | PTGS1PTGS2KMT2ASMN1; SMN2HPGD | |
| SCHEMBL23933300 | 0.91 | KMT2A (0.40) | PTGS1PTGS2KMT2ASMN1; SMN2HPGD | |
| SCHEMBL23933301 | 0.91 | KMT2A (0.40) | PTGS1PTGS2KMT2ASMN1; SMN2HPGD | |
| SCHEMBL30855386 | 0.90 | PTGS1 (0.37) | PTGS1PTGS2KMT2ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-3888689-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3735990-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | Abbvie Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2020-08-06 | — | — | US | disclosed |
| EP-3229844-B1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | ABBVIE INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190153107-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3468598-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468615-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468993-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017214456-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-3229844-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | AbbVie Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2017-06-29 | — | — | US | disclosed |
| WO-2016094505-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | PTGS1 3703/4885PTGS2 3421/4885KMT2A 1606/4885 |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | PTGS1 3464/4885PTGS2 3211/4885KMT2A 2285/4885 |
| US-20190153107-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | PTGS1 3703/4885PTGS2 3421/4885KMT2A 1606/4885 |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | PTGS1 3464/4885PTGS2 3211/4885KMT2A 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.